Patent application number | Description | Published |
20090005359 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 01-01-2009 |
20090036419 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 02-05-2009 |
20120040951 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 02-16-2012 |
20130065858 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 03-14-2013 |
20150080568 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 03-19-2015 |
20150203515 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS - Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). | 07-23-2015 |
20150210647 | ATX MODULATING AGENTS - Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer. | 07-30-2015 |
20150361029 | S1P MODULATING AGENTS - Compounds of formula (I) can modulate the activity of one or more S 1P receptors. Sphingosine 1-phosphate (S IP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family, namely S1P1, S1P2, S1P3, S1P4, and S1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDG8). The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (Ga.) subunits and beta-gamma (G( )y) dimers. | 12-17-2015 |